+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gabapentin Market by Route Of Administration (Oral, Parenteral), Formulation (Branded, Generic), Dosage Form, Distribution Channel, End User, Indication - Global Forecast 2025-2030- Product Image
Gabapentin Market by Route Of Administration (Oral, Parenteral), Formulation (Branded, Generic), Dosage Form, Distribution Channel, End User, Indication - Global Forecast 2025-2030- Product Image
Sale

Gabapentin Market by Route Of Administration (Oral, Parenteral), Formulation (Branded, Generic), Dosage Form, Distribution Channel, End User, Indication - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6016490
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gabapentin Market grew from USD 2.32 billion in 2024 to USD 2.43 billion in 2025. It is expected to continue growing at a CAGR of 4.39%, reaching USD 3.01 billion by 2030.

Unveiling the Strategic Importance of In-Depth Gabapentin Market Analysis to Inform Critical Stakeholder Decisions

Gabapentin has emerged as an essential therapy across a spectrum of neurological and pain-related disorders, underscoring the pressing need for a nuanced analysis of its industry dynamics. Over recent years, escalating demand for effective neuropathic pain management options has propelled gabapentin into the forefront of treatment protocols. Simultaneously, evolving regulatory requirements, patent expirations, and supply chain complexities have reshaped the competitive landscape.

Against this backdrop, understanding the interplay of formulation innovations, distribution channels, and patient demographics is paramount. Stakeholders ranging from pharmaceutical manufacturers to healthcare providers must navigate shifting global tariff regimes and regional market idiosyncrasies. A multifaceted assessment that integrates scientific advancements with commercial intelligence provides the foundation for informed decision-making.

This executive summary presents a cohesive narrative of the gabapentin market’s current state and future trajectory. It distills critical insights into transformative trends, tariff impacts, segmentation patterns, regional nuances, and competitive positioning, culminating in strategic recommendations designed to empower industry leaders.

Highlighting the Pivotal Scientific and Technological Transformations Reshaping the Gabapentin Value Chain Across Development and Delivery

In recent times, groundbreaking innovations have disrupted traditional paradigms in gabapentin research and commercialization. Advances in controlled-release formulations have enhanced therapeutic consistency, bolstering patient adherence and broadening clinical utility. Concurrently, the integration of pharmacogenomic data into prescribing practices has refined patient stratification, enabling personalized dosing and reducing adverse event risk.

Parallel to pharmaceutical advances, digital health platforms and telemedicine have expanded patient access to gabapentin therapies. Virtual consultations and remote monitoring tools now facilitate seamless dose titration and side effect management, particularly in underserved regions. This digital pivot is fostering new collaborative models between clinicians, payers, and manufacturers, ultimately accelerating product adoption.

Moreover, environmental sustainability has risen as a pivotal concern within the pharmaceutical supply chain. Green chemistry initiatives aim to reduce solvent waste and energy consumption during gabapentin synthesis, while circular economy principles guide packaging innovations to minimize pharmaceutical residue. These transformative shifts signal a new era of efficiency, patient-centricity, and ecological responsibility within the gabapentin market.

Analyzing the Influence of Newly Instituted US Tariffs on Gabapentin Raw Material Sourcing and Manufacturing Expenditures

The landscape of international trade for gabapentin is increasingly influenced by the introduction of novel tariff structures in the United States, scheduled for implementation in 2025. These levies aim to protect domestic manufacturing capacity but simultaneously introduce cost pressures for importers of active pharmaceutical ingredients. Consequently, the pricing models of downstream formulations may adjust, influencing procurement strategies and reimbursement negotiations.

Emerging tariff differentials could incentivize localized synthesis of gabapentin intermediates, driving investment in US-based production facilities. However, such nearshoring initiatives must contend with higher labor and compliance costs. Manufacturers are thus reevaluating supplier portfolios and exploring collaborative ventures with regional partners to mitigate the financial impact of new duties.

In response to these evolving trade policies, agile supply chain frameworks are becoming essential. Real-time monitoring of customs regulations, alternative sourcing routes, and flexible contract manufacturing agreements enable companies to adapt rapidly. Stakeholders who proactively integrate tariff risk assessments into their strategic planning will maintain resilience and cost competitiveness in the face of shifting trade regimes.

Elucidating Multi-Dimensional Segmentation in Gabapentin Therapeutics to Drive Precision Marketing and Product Differentiation

A detailed examination of the gabapentin market reveals distinct patterns across multiple dimensions of segmentation. Route of administration considerations underscore the predominance of orally administered therapies, while parenteral forms remain niche, catering to specialized clinical settings. Formulation insights highlight the competitive dynamics between branded and generic offerings as market exclusivities wane.

Dosage form differentiation further informs portfolio strategies, with capsules-divided into hard gelatin and soft gelatin variants-addressing diverse release profiles, while extended release and immediate release tablets optimize convenience and titration. Oral solutions provide additional flexibility for pediatric and geriatric populations. Distribution channel analysis emphasizes the strategic importance of hospital pharmacies for acute care, online pharmacies for direct-to-patient convenience, and retail pharmacies as the primary touchpoint for ongoing prescriptions.

Turning to end-user segmentation, clinics prioritize rapid-acting formulations for outpatient management, home care services demand easy-to-dispense dosage forms with clear dosing instructions, and hospitals focus on stringent quality standards and broad-spectrum inventory. Indication-based segmentation reveals epilepsy as a long-established use case, neuropathic pain-further categorized into diabetic neuropathy and postherpetic neuralgia-as a driving growth pillar, and restless leg syndrome presenting emerging therapeutic opportunities. Understanding these intersecting layers of market segmentation equips decision-makers to tailor offerings to specific clinical and distributional requirements.

Revealing Divergent Regional Dynamics Impacting Gabapentin Adoption and Market Growth Across Key Global Territories

Geographic analyses of gabapentin utilization and development reveal distinct regional trajectories. In the Americas, robust research infrastructure and progressive reimbursement frameworks have fostered widespread adoption, particularly within North America, where generics penetration is high. Latin American markets, while cost-sensitive, show increasing uptake as health authorities expand pain management guidelines.

The Europe, Middle East & Africa region presents a mosaic of regulatory environments, with Western Europe characterized by stringent market approvals and competitive local manufacturing, while Eastern Europe and North African countries are rapidly modernizing pharmaceutical distribution networks. Gulf Cooperation Council states are investing heavily in healthcare infrastructure, opening new channels for specialized gabapentin formulations.

In Asia-Pacific, a blend of emerging markets and established economies drives diverging demand patterns. Established markets such as Japan and Australia prioritize branded extended-release options, whereas China, India, and Southeast Asia exhibit strong generic growth fueled by government-led cost containment efforts. These regional nuances underscore the importance of custom-tailored strategies, from regulatory engagement to channel optimization, to maximize gabapentin’s market potential worldwide.

Examining Competitive Strategic Moves and Collaborations Defining the Leading Players’ Positioning in the Global Gabapentin Space

Leading pharmaceutical companies are strategically positioning themselves across the gabapentin value chain through targeted initiatives. Some legacy manufacturers are reinvesting in advanced formulation platforms to extend product lifecycles, while generic drugmakers are scaling production capacity to capitalize on demand growth. Collaboration agreements between originator firms and contract development organizations have accelerated time-to-market for novel gabapentin formulations.

Strategic alliances between regional distributors and local healthcare providers have ensured broader access in high-potential markets, particularly within emerging economies. Research-driven biopharmaceutical players are also exploring next-generation analogs and prodrugs to address unmet needs in neuropathic pain and refractory epilepsy. Moreover, several competitors are deploying digital patient engagement tools to differentiate their offerings and foster adherence monitoring capabilities.

Overall, the competitive landscape is defined by a balance between innovation-driven differentiation and cost-focused volume strategies. Companies that successfully integrate scientific advancements with agile commercialization tactics will consolidate market leadership in this dynamic environment.

Outlining Proactive Strategic Initiatives for Stakeholders to Strengthen Market Positioning and Navigate Emerging Gabapentin Challenges

Industry leaders should prioritize the development of extended-release delivery systems to enhance patient adherence while differentiating their portfolios from commoditized generics. Investing in green manufacturing processes will not only address environmental compliance mandates but also resonate with increasingly sustainability-conscious stakeholders.

Establishing flexible supply networks capable of rapid adjustment to tariff fluctuations is essential. By diversifying raw material sourcing and cultivating local manufacturing partnerships, companies can mitigate duty-related cost pressures and maintain stable supply. Furthermore, leveraging digital health platforms to support remote patient management and adherence tracking will strengthen therapeutic outcomes and foster patient loyalty.

Engaging proactively with regulators across diverse regions can expedite approvals and facilitate favorable reimbursement decisions. Tailoring market access strategies to reflect local healthcare policies and distribution models will optimize rollout timelines. Finally, formulating indication-specific value propositions-particularly in diabetic neuropathy and restless leg syndrome-will unlock niche opportunities and drive incremental revenue streams.

Detailing the Combined Qualitative and Quantitative Methodological Framework Underpinning the Gabapentin Market Assessment

This study integrates both qualitative and quantitative research methodologies to ensure robust, evidence-based conclusions. Primary insights were derived from in-depth interviews with industry veterans, key opinion leaders in neurology and pain management, regulatory experts, and supply chain specialists. These discussions provided nuanced perspectives on clinical adoption drivers, formulation trends, and tariff-related supply considerations.

Secondary data collection encompassed peer-reviewed scientific literature, regulatory filings, corporate disclosures, and trade association reports. Comprehensive analyses of patent landscapes and clinical trial registries were conducted to map innovation pipelines, while tariff schedules and customs data informed the assessment of trade impacts.

Analytical frameworks employed include competitor benchmarking, segmentation matrix analyses, and scenario planning for tariff fluctuation impacts. Triangulation of data sources and peer validation of findings ensured the credibility and relevance of the insights presented throughout this report.

Synthesizing Key Market Dynamics and Strategic Imperatives to Provide a Comprehensive Overview of the Gabapentin Sector’s Future Direction

The multifaceted narrative woven through this executive summary highlights the critical factors shaping the gabapentin landscape. From scientific breakthroughs in controlled-release and pharmacogenomics to the recalibration of supply chains in response to new tariff structures, the market is in a state of dynamic evolution. Segmentation insights illuminate precise opportunities across administration routes, formulations, dosage forms, distribution channels, end users, and indications.

Regional analysis underscores varied growth drivers in the Americas, Europe, Middle East & Africa, and Asia-Pacific, informing differentiated go-to-market approaches. Competitive assessment reveals a delicate equilibrium between innovation-led differentiation and cost-efficient generic proliferation. Actionable recommendations emphasize sustainable manufacturing, supply chain agility, digital engagement, and regulatory collaboration as cornerstones for future success.

Together, these insights form a strategic blueprint for stakeholders aiming to navigate complexity, seize emerging opportunities, and maintain resilience in the global gabapentin market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Oral
    • Parenteral
  • Formulation
    • Branded
    • Generic
  • Dosage Form
    • Capsules
      • Hard Gelatin
      • Soft Gelatin
    • Oral Solution
    • Tablets
      • Extended Release
      • Immediate Release
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Clinics
    • Home Care
    • Hospitals
  • Indication
    • Epilepsy
    • Neuropathic Pain
      • Diabetic Neuropathy
      • Postherpetic Neuralgia
    • Restless Leg Syndrome
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Apotex Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Zydus Lifesciences Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Alembic Pharmaceuticals Ltd.
  • Lupin Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of patented extended-release gabapentin formulations in neuropathic pain management
5.2. Escalating price competition among generic gabapentin manufacturers affecting market margins
5.3. Emerging clinical evidence supporting gabapentin use in treating fibromyalgia and off-label conditions
5.4. Regulatory agencies intensifying monitoring of gabapentin prescribing practices to curb misuse
5.5. Integration of digital adherence tools to optimize gabapentin therapy outcomes in chronic pain patients
5.6. Strategic partnerships between pharma and biotech firms to develop gabapentin combination therapies with improved efficacy
5.7. Supply chain innovations reducing lead times and ensuring consistent availability of gabapentin generics globally
5.8. Personalized medicine approaches leveraging genetic profiling to tailor gabapentin dosing regimens
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gabapentin Market, by Route Of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Gabapentin Market, by Formulation
9.1. Introduction
9.2. Branded
9.3. Generic
10. Gabapentin Market, by Dosage Form
10.1. Introduction
10.2. Capsules
10.2.1. Hard Gelatin
10.2.2. Soft Gelatin
10.3. Oral Solution
10.4. Tablets
10.4.1. Extended Release
10.4.2. Immediate Release
11. Gabapentin Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Gabapentin Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Gabapentin Market, by Indication
13.1. Introduction
13.2. Epilepsy
13.3. Neuropathic Pain
13.3.1. Diabetic Neuropathy
13.3.2. Postherpetic Neuralgia
13.4. Restless Leg Syndrome
14. Americas Gabapentin Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Gabapentin Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Gabapentin Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Teva Pharmaceutical Industries Ltd.
17.3.2. Viatris Inc.
17.3.3. Apotex Inc.
17.3.4. Sandoz International GmbH
17.3.5. Sun Pharmaceutical Industries Ltd.
17.3.6. Cipla Ltd.
17.3.7. Zydus Lifesciences Ltd.
17.3.8. Torrent Pharmaceuticals Ltd.
17.3.9. Alembic Pharmaceuticals Ltd.
17.3.10. Lupin Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. GABAPENTIN MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GABAPENTIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. GABAPENTIN MARKET: RESEARCHAI
FIGURE 28. GABAPENTIN MARKET: RESEARCHSTATISTICS
FIGURE 29. GABAPENTIN MARKET: RESEARCHCONTACTS
FIGURE 30. GABAPENTIN MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GABAPENTIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GABAPENTIN MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GABAPENTIN MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 111. CANADA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. CANADA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. CANADA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 114. CANADA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 115. CANADA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 116. CANADA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 117. CANADA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 118. CANADA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 119. CANADA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 120. CANADA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 121. CANADA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. CANADA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. CANADA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. CANADA GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. CANADA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 126. CANADA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 127. CANADA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 128. CANADA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 129. MEXICO GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 132. MEXICO GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 133. MEXICO GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 134. MEXICO GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 135. MEXICO GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 136. MEXICO GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 137. MEXICO GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 138. MEXICO GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 139. MEXICO GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. MEXICO GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. MEXICO GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. MEXICO GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. MEXICO GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 144. MEXICO GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 145. MEXICO GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 146. MEXICO GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 221. GERMANY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. GERMANY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. GERMANY GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 224. GERMANY GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 225. GERMANY GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. GERMANY GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. GERMANY GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 228. GERMANY GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 229. GERMANY GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 230. GERMANY GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 231. GERMANY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. GERMANY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. GERMANY GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. GERMANY GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. GERMANY GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 236. GERMANY GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 237. GERMANY GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 238. GERMANY GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 239. FRANCE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. FRANCE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. FRANCE GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 242. FRANCE GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 243. FRANCE GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 244. FRANCE GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 245. FRANCE GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 246. FRANCE GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 247. FRANCE GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 248. FRANCE GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 249. FRANCE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. FRANCE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. FRANCE GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. FRANCE GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. FRANCE GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 254. FRANCE GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 255. FRANCE GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 256. FRANCE GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 275. ITALY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. ITALY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. ITALY GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 278. ITALY GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 279. ITALY GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 280. ITALY GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 281. ITALY GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 282. ITALY GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 283. ITALY GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 284. ITALY GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 285. ITALY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. ITALY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. ITALY GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. ITALY GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. ITALY GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 290. ITALY GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 291. ITALY GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 292. ITALY GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 293. SPAIN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. SPAIN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. SPAIN GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 296. SPAIN GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 297. SPAIN GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 298. SPAIN GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 299. SPAIN GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 300. SPAIN GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 301. SPAIN GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 302. SPAIN GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 303. SPAIN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. SPAIN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. SPAIN GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. SPAIN GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. SPAIN GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 308. SPAIN GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 309. SPAIN GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 310. SPAIN GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 330. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 332. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 334. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 335. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 336. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 337. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 338. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 339. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 340. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 341. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 342. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 343. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 344. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 345. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 346. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 347. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 348. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 349. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 350. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 351. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 352. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 353. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 354. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 355. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 356. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 357. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 358. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 359. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 360. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 361. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 362. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 363. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
TABLE 364. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2030 (USD MILLION)
TABLE 365. DENMARK GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 366. DENMARK GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 367. DENMARK GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 368. DENMARK GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 369. DENMARK GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 370. DENMARK GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 371. DENMARK GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 372. DENMARK GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 373. DENMARK GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 374. DENMARK GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLIO

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Gabapentin market report include:
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Apotex Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Zydus Lifesciences Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Alembic Pharmaceuticals Ltd.
  • Lupin Ltd.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.43 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.01 Billion
Compound Annual Growth Rate4.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gabapentin Market Size, Share & Trends Analysis Report By Dosage Form, By Type, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Gabapentin Market Size, Share & Trends Analysis Report By Dosage Form, By Type, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Gabapentin - Global Strategic Business Report - Product Image

Gabapentin - Global Strategic Business Report

  • Report
  • 477 Pages
  • Global
From
Gabapentin Global Market Report 2025 - Product Image

Gabapentin Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Gabapentin Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Gabapentin Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Gabapentin Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Gabapentin Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 99 Pages
  • Global
From

About the Gabapentin Market

Gabapentin is a medication used to treat certain types of seizures and nerve pain. It is a central nervous system (CNS) drug, meaning it acts on the brain and spinal cord to produce its effects. It is used to treat epilepsy, neuropathic pain, hot flashes, and restless leg syndrome. It is also used off-label to treat anxiety and insomnia. Gabapentin is generally well-tolerated, but can cause side effects such as dizziness, drowsiness, and confusion. Gabapentin is available in both generic and brand-name forms. It is available in capsule, tablet, and oral solution forms. It is also available as an extended-release tablet, which is taken once daily. The market for Gabapentin is highly competitive, with many companies offering generic and brand-name versions of the drug. Some of the companies in the market include Pfizer, Mylan, Teva Pharmaceuticals, Sun Pharmaceuticals, and Lupin Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.